<DOC>
	<DOCNO>NCT00080886</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy , carmustine , cytarabine , etoposide , melphalan , work different way stop cancer cell divide stop grow die . Combining rituximab combination chemotherapy autologous stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness combine rituximab combination chemotherapy follow autologous hematopoietic stem cell transplantation treat patient B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Carmustine , Cytarabine , Etoposide , Melphalan Followed By Autologous Hematopoietic Stem Cell Transplantation Treating Patients With B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine level soluble CD20 antigen ( sCD20 ) blood treatment rituximab carmustine , cytarabine , etoposide , melphalan follow autologous hematopoietic stem cell transplantation patient CD20-positive B-cell non-Hodgkin 's lymphoma . - Correlate effect change level sCD20 clinical outcome patient treat regimen . - Determine response rate patient treat regimen . - Determine event-free survival patient treat regimen . - Determine toxicity profile regimen patient . OUTLINE : Patients receive rituximab IV approximately 3-4 hour weekly 2 week follow 1 week later hematopoietic stem cell bone marrow harvest . Patients receive third dose rituximab IV approximately 3-4 hour day -7 -6 . Patients also receive high-dose chemotherapy comprise carmustine IV day -6 , cytarabine IV etoposide IV twice daily day -5 -2 , melphalan IV day -1 . Patients undergo autologous hematopoietic stem cell transplantation day 0 . Patients less complete remission day 100 post-transplantation receive 4 additional dos rituximab IV approximately 3-4 hour weekly 4 week . Patients follow day 100 , 1 year , annually thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonHodgkin 's lymphoma Any B cell CD20positive disease Failed prior primary induction therapy Meets 1 follow criterion : Chemotherapyrefractory disease Received least 3 prior chemotherapy regimens Mantle cell lymphoma Eligible transplantation No history Tcell lymphoma PATIENT CHARACTERISTICS : Age 19 Performance status WHO 02 Life expectancy At least 6 month Hematopoietic Absolute neutrophil count â‰¥ 1,000/mm^3* Platelet count &gt; 50,000/mm^3* Hemoglobin &gt; 9.0 g/dL* NOTE : *Unless due lymphomatous involvement bone marrow Hepatic Not specify Renal Not specify Other Not pregnant nursing Fertile patient must use 2 method effective contraception No concurrent serious disease condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>